Close Menu

No matter how the market flourishes or how promising a technology’s outlook, there’s still one thing that can bring even the most high-flying genomics execs to their knees. It’s the US FDA, headed up by Bernard Schwetz, acting principal deputy commissioner. His years of toxicology research experience have prepared him for what may be the coming onslaught of genomics-based drugs. He recently agreed to an e-mail interview with GT’s Meredith Salisbury.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

Newsweek discusses the privacy issues raised by digital medicine.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.